WALTHAM, Mass., Aug. 1 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN) announced today that the Company President and Chief
Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call
and webcast on Tuesday, August 8th, 2006 at 11:00 a.m. EDT, to report first
quarter fiscal year 2007 financial results and to provide a quarterly
update of the Company.
This call is being webcast by CCBN and can be accessed via Repligen's
website at http://www.repligen.com. If you are unable to access the webcast
via the internet, you may also listen to the live broadcast by calling
(800) 706-7749 for domestic calls and (617) 614-3474 for international
calls. Participants must provide the following passcode: 73128522. For
those who cannot participate in the live conference call, an archive of the
audio webcast will be available shortly after the call and may be accessed
at http://www.repligen.com.
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company committed to being
the leader in the development of novel therapeutics for profound
neuropsychiatric disorders and autoimmune disease. Repligen has a Specialty
Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the
profits from which will be used to partially support the development of our
proprietary products. Repligen's corporate headquarters are located at 41
Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional
information may be requested from http://www.repligen.com.
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. The forward-looking statements in this release do not
constitute guarantees of future performance. Investors are cautioned that
statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding current or
future financial performance and position, management's strategy, plans and
objectives for future operations, plans and objectives for product
development, plans and objectives for present and future clinical trials
and results of such trials, plans and objectives for regulatory approval,
litigation, intellectual property, product development, manufacturing plans
and performance such as the anticipated growth in the monoclonal antibody
market and our other target markets and projected growth in product sales,
constitute forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated, including, without
limitation, risks associated with: the success of current and future
collaborative relationships, the market acceptance of our products, our
ability to compete with larger, better financed pharmaceutical and
biotechnology companies, new approaches to the treatment of our targeted
diseases, our expectation of incurring continued losses, our uncertainty of
product revenues and profits, our ability to generate future revenues, our
ability to raise additional capital to continue our drug development
programs, the success of our clinical trials, our ability to develop and
commercialize products, our ability to obtain required regulatory
approvals, our compliance with all Food and Drug Administration
regulations, our ability to obtain, maintain and protect intellectual
property rights for our products, the risk of litigation regarding our
intellectual property rights, our limited sales and manufacturing
capabilities, our dependence on third-party manufacturers and value added
resellers, our ability to hire and retain skilled personnel, our volatile
stock price, and other risks detailed in Repligen's filings with the
Securities and Exchange Commission. Repligen assumes no obligation to
update any forward-looking information contained in this press release or
with respect to the announcements described herein.
SOURCE Repligen Corporation
 back to top
Related links:
http://www.repligen.com
CONTACT:
Walter C. Herlihy, Ph.D., President and Chief
Executive Officer, +1-781-419-1900, or Laura Whitehouse, Vice
President, Market Development, +1- 781-419-1812, both of Repligen
Corporation
|
